ATILMOTIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C86H134N20O19
Molecular Weight	1752.1101
Optical Activity	UNSPECIFIED
Defined Stereocenters	15 / 15
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@]([H])(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CC3=CC=CC=C3)[N+](C)(C)C)C(C)C)[C@@H](C)CC)([C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(O)C=C4)C(=O)NCC(=O)N[C@@H](CCC([O-])=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O

InChI

InChIKey=DUQRILZXKXSRIY-RUBJUKRASA-N

InChI=1S/C86H134N20O19/c1-13-51(8)71(103-81(121)65-30-23-41-105(65)85(125)70(50(6)7)102-82(122)66(106(10,11)12)46-54-26-18-15-19-27-54)83(123)101-64(44-53-24-16-14-17-25-53)80(120)104-72(52(9)107)84(124)100-63(45-55-31-33-56(108)34-32-55)74(114)93-47-68(110)94-59(36-38-69(111)112)76(116)99-62(43-49(4)5)79(119)97-60(35-37-67(88)109)77(117)96-58(29-22-40-92-86(90)91)75(115)98-61(42-48(2)3)78(118)95-57(73(89)113)28-20-21-39-87/h14-19,24-27,31-34,48-52,57-66,70-72,107H,13,20-23,28-30,35-47,87H2,1-12H3,(H21-,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124)/t51-,52+,57-,58+,59-,60-,61-,62-,63-,64-,65-,66-,70-,71-,72-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C86H134N20O19
Molecular Weight	1752.1101
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	15 / 15
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16371080 | https://www.ncbi.nlm.nih.gov/pubmed/19997977

Atilmotin (also known as BAX-ACC-1638), a motilin receptor agonist, is short acting, with t1/2 less than 10 min. It was shown that at doses of 6, 30 or 60 mg intravenously, it affected esophageal, lower esophageal sphincter (LES), and gastric motility. LES and gastric pressures were increased, whereas there was disruption of esophageal peristalsis characterized by lower amplitude and failed contractions. The drug can have the clinical implementation for stomach motility disorders but is needed further study.

Approval Year

PubMed

Title	Date	PubMed
Effect of atilmotin, a motilin receptor agonist, on esophageal, lower esophageal sphincter, and gastric pressures.	2010-02	19997977
New motilin agonists: a long and winding road.	2006-01	16371077

Sample Use Guides

In Vivo Use Guide

i.v. atilmotin, 6, 30, 60 microg or vehicle (placebo) given 2 min after standardized breakfast, lunch and dinner

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:37:08 GMT 2025` Edited by `admin` on `Wed Apr 02 07:37:08 GMT 2025`
Record UNII	4WQQ18VL49
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

ATILMOTIN

Official Name

English

BAX-ACC-1638

Preferred Name

English

L-LYSINAMIDE, N-((2S)-1-OXO-3-PHENYL-2-(TRIMETHYLAMMONIO)PROPYL)-L-VALYL-L-PROLYL-L-ISOLEUCYL-L-PHENYLALANYL-L-THREONYL-L-TYROSYLGLYCYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-GLUTAMINYL-D-ARGINYL-L-LEUCYL-

Systematic Name

English

ATILMOTIN [USAN]

Common Name

English

atilmotin [INN]

Common Name

English

Atilmotin [WHO-DD]

Common Name

English

OHM-11638

Code

English

MOT-288

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C548